Staging Alzheimer's Disease Risk by Sequencing Brain Function and Structure, Cerebrospinal Fluid, and Cognition Biomarkers. J Alzheimers Dis 2016 Oct 04;54(3):983-993
Date
08/29/2016Pubmed ID
27567874Pubmed Central ID
PMC5055443DOI
10.3233/JAD-160537Scopus ID
2-s2.0-84990038434 (requires institutional sign-in at Scopus site) 29 CitationsAbstract
This study aims to develop a composite biomarker that can accurately measure the sequential biological stages of Alzheimer's disease (AD) on an individual level. We selected 144 subjects from the Alzheimer's Disease Neuroimaging Initiative 2 datasets. Ten biomarkers, from brain function and structure, cerebrospinal fluid, and cognitive performance, were integrated using the event-based probabilistic model to estimate their optimal temporal sequence (Soptimal). We identified the numerical order of the Soptimal as the characterizing Alzheimer's disease risk events (CARE) index to measure disease stage. The results show that, in the Soptimal, hippocampal and posterior cingulate cortex network biomarkers occur first, followed by aberrant cerebrospinal fluid amyloid-β and p-tau levels, then cognitive deficit, and finally regional gray matter loss and fusiform network abnormality. The CARE index significantly correlates with disease severity and exhibits high reliability. Our findings demonstrate that use of the CARE index would advance AD stage measurement across the whole AD continuum and facilitate personalized treatment of AD.
Author List
Chen G, Shu H, Chen G, Ward BD, Antuono PG, Zhang Z, Li SJ, Alzheimer’s Disease Neuroimaging InitiativeAuthor
Piero G. Antuono MD Professor in the Neurology department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AgedAged, 80 and over
Alzheimer Disease
Biomarkers
Brain
Cognition
Cognitive Dysfunction
Databases, Factual
Female
Humans
Male
Middle Aged
Risk Factors
